Speaker illustration

Mr Daniel Tobias Michaeli

University Medical Centre of Mannheim, Mannheim (Germany)

Future medical doctor holding a B.Sc. & M.Sc. in Management & Biochemistry and a M.Sc. in International Health Policy (Health Economics) from TUM, LSE, MIT, and Heidelberg University. Prior experience in venture capital, private equity, consulting, and hedge funds focusing on the life science and biopharmaceutical industry. Previous research focused on drug development, oncology, cardiology, and health policy with +20 peer-reviewed publications.

Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK

Event: ESC Congress 2022

Topic: Health Economics

Session: Costs and cost-effectiveness


Cost-effectiveness of cholesterol-lowering drugs for secondary cardiovascular prevention in the UK: ezetimibe, evolocumab, and alirocumab

Event: ESC Congress 2022

Topic: Drug therapy

Session: Lipids - Drug therapy 1


This platform is supported by

logo Novo Nordisk